Of interest, FGFR4 inhibitors are currently being developed and tested in cancer, opening potential for downstream targeting of high FGF23 levels in CKD patients to prevent the development of left ventricular hypertrophy and heart failure [63,64▪▪]. The gene discussed is FGF23; the disease is left ventricular hypertrophy.